SC
ALLO icon

Stralem & Co’s Allogene Therapeutics ALLO Stock Holding History

Stralem & Co’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$71K Hold
1,650
– – 0.05% 51
2020
Q1 		$32K Buy
+1,650
New +$39.3K 0.02% 54

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

Stralem & Co's ALLO Position: Q2 2020 in Review

Stralem & Co held its Allogene Therapeutics (ALLO) position steady in Q2 2020 at 1,650 shares worth $71K. The position accounts for 0.05% of the portfolio, ranked #51.

Stralem & Co first reported a position in ALLO in Q1 2020 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold ALLO as of Q2 2020.

  • Stralem & Co held 1,650 shares of Allogene Therapeutics worth $71K as of Q2 2020.
  • Stralem & Co left its Allogene Therapeutics share count unchanged in Q2 2020.
  • Allogene Therapeutics made up 0.05% of Stralem & Co's portfolio in Q2 2020, its #51 holding.
  • Stralem & Co first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.